TY - JOUR
T1 - Revisiting Alpha-Synuclein Pathways to Inflammation
AU - Lyra, Patrícia
AU - Machado, Vanessa
AU - Rota, Silvia
AU - Chaudhuri, Kallol Ray
AU - Botelho, João
AU - Mendes, José João
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/4
Y1 - 2023/4
N2 - Alpha-synuclein (α-Syn) is a short presynaptic protein with an active role on synaptic vesicle traffic and the neurotransmitter release and reuptake cycle. The α-Syn pathology intertwines with the formation of Lewy Bodies (multiprotein intraneuronal aggregations), which, combined with inflammatory events, define various α-synucleinopathies, such as Parkinson’s Disease (PD). In this review, we summarize the current knowledge on α-Syn mechanistic pathways to inflammation, as well as the eventual role of microbial dysbiosis on α-Syn. Furthermore, we explore the possible influence of inflammatory mitigation on α-Syn. In conclusion, and given the rising burden of neurodegenerative disorders, it is pressing to clarify the pathophysiological processes underlying α-synucleinopathies, in order to consider the mitigation of existing low-grade chronic inflammatory states as a potential pathway toward the management and prevention of such conditions, with the aim of starting to search for concrete clinical recommendations in this particular population.
AB - Alpha-synuclein (α-Syn) is a short presynaptic protein with an active role on synaptic vesicle traffic and the neurotransmitter release and reuptake cycle. The α-Syn pathology intertwines with the formation of Lewy Bodies (multiprotein intraneuronal aggregations), which, combined with inflammatory events, define various α-synucleinopathies, such as Parkinson’s Disease (PD). In this review, we summarize the current knowledge on α-Syn mechanistic pathways to inflammation, as well as the eventual role of microbial dysbiosis on α-Syn. Furthermore, we explore the possible influence of inflammatory mitigation on α-Syn. In conclusion, and given the rising burden of neurodegenerative disorders, it is pressing to clarify the pathophysiological processes underlying α-synucleinopathies, in order to consider the mitigation of existing low-grade chronic inflammatory states as a potential pathway toward the management and prevention of such conditions, with the aim of starting to search for concrete clinical recommendations in this particular population.
KW - Parkinson’s disease
KW - alpha-synuclein
KW - inflammation
KW - neuroinflammation
KW - synucleinopathies
KW - Lewy Bodies/metabolism
KW - Humans
KW - Parkinson Disease/metabolism
KW - Inflammation/metabolism
KW - alpha-Synuclein/metabolism
KW - Synucleinopathies/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85158021435&partnerID=8YFLogxK
U2 - 10.3390/ijms24087137
DO - 10.3390/ijms24087137
M3 - Review article
C2 - 37108299
AN - SCOPUS:85158021435
SN - 1661-6596
VL - 24
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 8
M1 - 7137
ER -